Pacer Advisors Portfolio holdings
AUM
$39.6B
1-Year Return
5.04%
This Quarter Return
-4.31%
1 Year Return
+5.04%
3 Year Return
+42.86%
5 Year Return
+91.64%
10 Year Return
+332.32%
AUM
$43.7B
AUM Growth
+$158M
(+0.36%)
Cap. Flow
+$1.17B
Cap. Flow
% of AUM
2.67%
Top 10 Holdings %
Top 10 Hldgs %
11.64%
Holding
4,109
New
199
Increased
895
Reduced
1,260
Closed
190
Top Buys
| 1 |
Hewlett Packard
HPE
|
$488M |
| 2 |
Halliburton
HAL
|
$458M |
| 3 |
Archer Daniels Midland
ADM
|
$456M |
| 4 |
Gen Digital
GEN
|
$413M |
| 5 |
WESCO International
WCC
|
$251M |
Top Sells
| 1 |
Vistra
VST
|
$614M |
| 2 |
Exxon Mobil
XOM
|
$498M |
| 3 |
Chevron
CVX
|
$435M |
| 4 |
Occidental Petroleum
OXY
|
$432M |
| 5 |
Cisco
CSCO
|
$411M |
Sector Composition
| 1 | Consumer Discretionary | 17.28% |
| 2 | Technology | 17.14% |
| 3 | Energy | 14.05% |
| 4 | Industrials | 10.98% |
| 5 | Healthcare | 9.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1351
Qiagen
QGEN
$10.2B
| $12.4K | ﹤0.01% |
294
+35
| +14% | +$1.48K |
|
1352
Couchbase
BASE
$1.35B
| $11.8K | ﹤0.01% |
+646
| New | +$11.8K |
|
1353
Day One Biopharmaceuticals
DAWN
$759M
| $11.7K | ﹤0.01% |
851
-51
| -6% | -$703 |
|
1354
iShares MSCI Taiwan ETF
EWT
$6.16B
| $11.5K | ﹤0.01% |
212
+4
| +2% | +$217 |
|
1355
4D Molecular Therapeutics
FDMT
$309M
| $11.4K | ﹤0.01% |
544
-185
| -25% | -$3.88K |
|
1356
Prothena Corp
PRTA
$442M
| $11.4K | ﹤0.01% |
552
-858
| -61% | -$17.7K |
|
1357
InMode
INMD
$911M
| $11.3K | ﹤0.01% |
620
-30
| -5% | -$547 |
|
1358
Unity
U
$17B
| $11.1K | ﹤0.01% |
682
+214
| +46% | +$3.48K |
|
1359
Arcturus Therapeutics
ARCT
$455M
| $10.8K | ﹤0.01% |
444
-287
| -39% | -$6.99K |
|
1360
Rush Street Interactive
RSI
$2.05B
| $10.8K | ﹤0.01% |
1,123
-496
| -31% | -$4.76K |
|
1361
Viridian Therapeutics
VRDN
$1.52B
| $10.7K | ﹤0.01% |
825
-1,075
| -57% | -$14K |
|
1362
iShares MSCI UAE ETF
UAE
$166M
| $10.7K | ﹤0.01% |
779
+392
| +101% | +$5.39K |
|
1363
Sana Biotechnology
SANA
$757M
| $10.6K | ﹤0.01% |
1,936
-373
| -16% | -$2.04K |
|
1364
MannKind Corp
MNKD
$1.64B
| $10.4K | ﹤0.01% |
1,993
-1,415
| -42% | -$7.39K |
|
1365
Cullinan Oncology
CGEM
$408M
| $10.4K | ﹤0.01% |
595
+145
| +32% | +$2.53K |
|
|
EVRI
1366
DELISTED
Everi Holdings
EVRI
| $10.3K | ﹤0.01% |
1,227
+96
| +8% | +$806 |
|
1367
Xencor
XNCR
$597M
| $10.3K | ﹤0.01% |
543
-521
| -49% | -$9.86K |
|
1368
SGHC Ltd
SGHC
$6.03B
| $10.2K | ﹤0.01% |
3,146
+495
| +19% | +$1.6K |
|
1369
Praxis Precision Medicines
PRAX
$970M
| $9.72K | ﹤0.01% |
+235
| New | +$9.72K |
|
1370
CG Oncology
CGON
$2.36B
| $9.16K | ﹤0.01% |
+290
| New | +$9.16K |
|
1371
Vir Biotechnology
VIR
$714M
| $9.15K | ﹤0.01% |
1,028
-1,175
| -53% | -$10.5K |
|
1372
Spyre Therapeutics
SYRE
$1.03B
| $8.98K | ﹤0.01% |
+382
| New | +$8.98K |
|
1373
Cogent Biosciences
COGT
$1.81B
| $8.82K | ﹤0.01% |
1,046
-2,233
| -68% | -$18.8K |
|
1374
Bally's
BALY
$491M
| $8.73K | ﹤0.01% |
729
-85
| -10% | -$1.02K |
|
1375
Travere Therapeutics
TVTX
$1.89B
| $8.52K | ﹤0.01% |
1,037
-1,734
| -63% | -$14.3K |
|